Pfizer Inc (PFE)

Nov 13, 2026

Novo Nordisk has filed for approval of its oral pyruvate kinase-R (PKR) activator, etavopivat, for sickle cell disease (SCD) with both the FDA and EMA. This move positions Novo Nordisk in direct competition with Agios Pharmaceuticals, whose own candidate, mitapivat, recently experienced a delay in its FDA decision. The article highlights the intensifying race to market an oral PKR activator for SCD between the two pharmaceutical companies.

Nov 13, 2026

Moderna's shares fell after its 2026 Analyst Day, where it outlined a cost outlook for 2027 and beyond, but provided limited visibility into future revenue growth. While oncology, particularly its personalized cancer therapy intismeran autogene with Merck, is highlighted as a key long-term growth driver, investors were concerned by the projected spending without a clear revenue forecast. The company also continues to expand its infectious disease vaccine portfolio and expects 2026 revenues to grow 15-25%.

Nov 13, 2026

Moderna's shares fell after its 2026 Analyst Day, where the company highlighted oncology as a key long-term growth opportunity and outlined cost expectations for 2027 through 2030, but provided limited visibility into future revenue growth. The company is advancing a personalized cancer therapy with Merck and expanding its infectious disease vaccine portfolio. Despite a projected 15-25% revenue growth for 2026, investors were concerned about the lack of specific revenue forecasts for subsequent years amidst significant planned investments in oncology.

Nov 13, 2026

Pfizer (NYSE:PFE) has announced it will no longer sell its Premarin hormone replacement therapy in Canada following an internal review, ceasing availability of both its vaginal cream and oral tablets. This discontinuation, alongside existing shortages of other estradiol patches, is expected to strain Canada’s menopause drug supply, although Pfizer states its decision was not due to new safety concerns. Current inventories of Premarin oral tablets are projected to last until mid-2027, with alternative treatments still available.

Nov 13, 2026

Bristol Myers Squibb (BMY) will merge its research and development organizations under Chief Medical Officer Cristian Massacesi, effective January 1, 2027. Robert Plenge, the current chief research officer, will advise through March 2027 before leaving the company. This restructuring aims to integrate scientific and clinical expertise, accelerate decision-making, and enhance portfolio execution for long-term growth.

Nov 13, 2026

Swiss biotech Windward Bio successfully raised $225 million in its IPO, with shares set to trade on Nasdaq. The company plans to use the proceeds to advance its respiratory drug candidates, WIN378 and WIN027, which target TSLP and IL-13 pathways, both acquired from Chinese biotechs. Meanwhile, another biotech, Rezera, postponed its IPO due to unfavorable market conditions.

Nov 13, 2026

Teva Pharmaceutical Industries EVP Richard Daniell sold 20,003 shares of the company's stock for over $856,000, reducing his direct stake by 26.4%. This follows an earlier sale of 25,000 shares. The company recently surpassed quarterly earnings and revenue expectations, and analysts maintain a generally positive outlook with an average target price of $48.15.

Nov 12, 2026

Amgen's stock is analyzed against its peers, including Johnson & Johnson, AbbVie, Merck, Pfizer, and Bristol Myers Squibb. The article highlights that Amgen, despite ranking second in revenue growth and operating margin among its peers, has a lower P/E ratio compared to Johnson & Johnson. This suggests that investors are paying less for Amgen's profit, even with its strong performance driven by a few fast-growing medicines and a raised 2026 revenue forecast.

Nov 12, 2026

Pfizer has announced it will stop selling its Premarin hormone replacement therapy products in Canada following an internal review, a decision not related to safety concerns. This discontinuation, alongside existing shortages of other hormone therapy products, is expected to add pressure to Canada's menopause drug supply. The company stated that existing stock of Premarin tablets should last until mid-2027, but supply could deplete faster due to increasing demand.

Nov 12, 2026

Pfizer has partnered with Blackstone, securing up to $1.5 billion in funding for berobenatide, a monthly GLP-1 agonist for obesity. Despite the potential advantages of berobenatide's dosing and manufacturing costs, concerns remain regarding safety and efficacy data compared to existing competitors. With Pfizer facing stagnant revenues, high debt, and impending patent expirations, the success of its GLP-1 program is crucial, though its prospects are considered speculative.

Nov 12, 2026

Eli Lilly has secured NMPA approval for its oral weight loss pill, orforglipron (Foundayo), in China, making it the first oral GLP-1RA to achieve this in the country. This positions Lilly ahead of rival Novo Nordisk, which is also seeking approval for its oral Wegovy in China. While Novo Nordisk was first to market globally with an oral GLP-1RA, analysts predict that Foundayo will eventually surpass oral Wegovy in sales, potentially reaching over $21 billion for Lilly by 2032.

Nov 12, 2026

Pfizer and Blackstone Life Sciences have entered a co-funding agreement where Blackstone will provide up to $1.5 billion through 2028 to advance berobenatide, Pfizer's investigational monthly GLP-1 receptor agonist peptide for chronic weight management. In return, Blackstone will receive milestone-based payments tied to U.S. regulatory approval and commercial sales. Pfizer maintains full operational control and ownership of berobenatide, which is currently in Phase III trials for obesity and related comorbidities.

Nov 12, 2026

Pfizer Inc. (NYSE: PFE) and Blackstone Life Sciences have entered a co-funding agreement where Blackstone will provide up to $1.5 billion by 2028 for the development of berobenatide, Pfizer's investigational GLP-1 receptor agonist peptide for chronic weight management. In return, Blackstone will receive milestone-based payments contingent on U.S. regulatory approval and commercial sales. Pfizer plans over 20 trials for berobenatide, including Phase 3 studies, following encouraging Phase 2b data that showed an average non-placebo-adjusted weight loss of 15.9%.

Nov 12, 2026

Bristol Myers Squibb is reorganizing its R&D unit, combining all research and development efforts under one leader, Chief Medical Officer Cristian Massacesi. This move comes as Chief Research Officer Robert Plenge departs at the end of the year, with the company facing pressure to replenish its pipeline ahead of looming patent expirations for key blockbusters Opdivo and Eliquis. The restructure aims to accelerate pipeline development by integrating scientific and clinical expertise.

Nov 12, 2026

Pfizer and Blackstone Life Sciences have entered a co-funding agreement where Blackstone-managed funds will contribute up to $1.5 billion towards the R&D of berobenatide, an investigational monthly injection for chronic weight management. In return, Blackstone could receive payments tied to U.S. regulatory approval and commercial sales milestones, but Pfizer will retain full control and ownership of the drug. This collaboration aims to advance Pfizer's comprehensive obesity program while maintaining financial flexibility for its broader pipeline.

Nov 12, 2026

Amgen's experimental drug, dazodalipeb, has shown promise as a first-in-class treatment for Sjögren’s disease, with positive Phase III results demonstrating significant improvements in systemic disease activity and self-reported dryness. The drug, acquired as part of the Horizon Pharma takeover, met its primary endpoint in two dosing regimens and was generally well-tolerated. This positions dazodalipeb as a strong contender in the race to market for Sjögren's, potentially outperforming competitor drugs currently under regulatory review.

Nov 12, 2026

Eli Lilly has reportedly secured Chinese regulatory approval for its oral GLP-1 weight-loss drug, orforglipron, making it the first drugmaker to receive such clearance in the country. This approval gives Eli Lilly a significant lead over competitors like Novo Nordisk in the Chinese market for weight-loss pills.

Nov 12, 2026

Pfizer has secured up to $1.5 billion from Blackstone Life Sciences to fund the development of its monthly GLP-1 receptor agonist, berobenatide, as it races to compete in the obesity drug market. This financing will cover development costs through 2028, with Blackstone potentially earning milestones tied to U.S. approval and commercial sales targets. The agreement allows Pfizer to preserve financial flexibility while investing in its obesity franchise, especially as it faces upcoming patent expirations.

Nov 11, 2026

Pfizer has secured up to $1.5 billion from Blackstone to fund the development of berobenatide, an experimental monthly injectable obesity treatment. The funding, provided through 2028, will not grant Blackstone any rights or ownership in the drug but will make them eligible for milestone-based payments tied to regulatory approval and commercial sales. This deal offers Pfizer greater flexibility to invest in its broader pipeline while retaining full control over the obesity medication's development.

Nov 11, 2026

Pfizer has secured up to $1.5 billion from Blackstone Life Sciences to fund the development of its investigational GLP-1 receptor drug, berobenatide. This investment will cover development costs for the drug, which is being studied for chronic weight management and obesity-related conditions. Pfizer aims to advance over 20 trials for obesity and related conditions in 2026.

Nov 11, 2026

This article compares Kimberly-Clark (KMB) and Colgate-Palmolive (CL) as dividend stocks, focusing on which would pay more over a decade. KMB currently offers a higher yield (4.6% vs. 2.2%) but has a tighter dividend payout ratio, especially after its recent Kenvue acquisition. CL, while having a lower yield, boasts a more robust cash flow coverage for its dividend. Despite KMB's integration risks, the analysis concludes that its higher initial yield would likely result in greater total dividend payments over 10 years, assuming both companies maintain their historical dividend growth rates.

Nov 11, 2026

Pfizer has secured up to $1.5 billion from Blackstone to fund the development of berobenatide, an experimental monthly injectable obesity treatment acquired through its Metsera acquisition. This funding provides Pfizer with greater flexibility for its broader pipeline while retaining full control over the drug's development. Blackstone will receive milestone-based payments contingent on US regulatory approval for monthly dosing and achievement of specific commercial sales targets.

Nov 11, 2026

Eli Lilly and Co and Gilead Sciences Inc are facing immediate drug pricing risks due to Medicare's expanding negotiation program, particularly with two Lilly drugs and Gilead's HIV treatment, Biktarvy, on the negotiation list. Meanwhile, Merck & Co and Bristol-Myers Squibb Co face larger financial consequences in later pricing cycles, with their key drugs, Keytruda and Opdivo, becoming eligible for negotiations in 2029. The upcoming November 30 announcement of negotiated prices is a critical milestone for investors as congressional scrutiny and government policies continue to pressure drugmakers.

Nov 11, 2026

BridgeBio Pharma will present 28 abstracts on acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) at the XX International Symposium on Amyloidosis (ISA) 2026. The data will highlight acoramidis's differentiated clinical profile, including its safety and efficacy in patients with chronic kidney disease, effects on cardiorenal function, and real-world outcomes compared to other treatments. These presentations aim to reinforce acoramidis as a leading first-line treatment option for ATTR-CM.

Nov 11, 2026

Arvinas, Inc. (Nasdaq: ARVN) announced its management will participate in a fireside chat at the Jefferies Global Healthcare Conference on November 18, 2026. The company is a clinical-stage biotechnology firm focused on targeted protein degradation to develop new drugs. A live audio webcast of the presentation will be available for interested parties.

Nov 11, 2026

Johnson & Johnson (J&J) is planning to submit Caplyta to the FDA for a potential label expansion to include the treatment of manic episodes in bipolar type I. This move follows the success of Caplyta in a Phase III trial for bipolar mania. If approved, this expansion would broaden the therapeutic scope of Caplyta, which is already used to treat schizophrenia and depressive episodes associated with bipolar I or II disorder.

Nov 11, 2026

Pfizer's stock (PFE) has significantly underperformed the S&P 500 over the past five years, even with dividends reinvested. While Pfizer's dividends added more to its return than the S&P 500's, the market's overall growth, including its own dividends, left Pfizer holders 87.8 percentage points behind. The article concludes that for income holders, the critical metric is Pfizer's total return with dividends compared to the S&P 500's, rather than the dividend yield alone.

Nov 10, 2026

Pfizer Inc. is investing $650 million over the next five years to build a new 220,000-sq-ft manufacturing technology center at its R&D campus in Groton, Connecticut. This facility will produce clinical active pharmaceutical ingredients and drug products for global clinical trials, while also modernizing infrastructure and consolidating existing employees. Construction is set to begin in Q2 2027, with operations expected to start in mid-2031.

Nov 10, 2026

As the stock market shows signs of weakness with the S&P 500 down 5% from its high, investors are increasingly concerned about a potential market crash. This article recommends three high-yielding dividend stocks—Realty Income (NYSE:O), Chevron (NYSE:CVX), and Pfizer (NYSE:PFE)—as safe long-term options. These companies offer robust dividends, solid fundamentals, and diversification benefits, making them suitable for investors looking for stability amidst market volatility.

Nov 10, 2026

Beam Therapeutics announced positive topline data from its Phase I/II BEACON trial for ristoglogene autogetemcel (risto-cel), a cell therapy for sickle cell disease (SCD). The therapy successfully met its primary and secondary endpoints, demonstrating freedom from severe vaso-occlusive crises for at least 12 consecutive months. Based on these results, Beam plans to submit a biologics license application (BLA) to the US FDA by the end of 2026, aiming to be the first base editing therapy approved.

Nov 10, 2026

Protalix BioTherapeutics reported strong financial results for Q3 2026, with revenues reaching $21.9 million, an increase from $17.9 million in Q3 2025, primarily due to higher Elfabrio sales. The company achieved a net income of $4 million and maintained a healthy cash position of $48.5 million with no debt. Protalix is focused on expanding Elfabrio's market presence and advancing PRX115 for uncontrolled gout, which is currently in a Phase 2 study with promising Phase 1 data.

Nov 10, 2026

Pfizer is set to invest $650 million in a new 220,000-square-foot manufacturing technology center at its research and development campus in Groton, Connecticut. Despite this significant investment outside the state, Massachusetts economic development officials are not worried about the Bay State's ability to compete for biotech and pharmaceutical business. Pfizer maintains a substantial presence in Massachusetts with R&D and manufacturing sites in Andover and Cambridge.

Nov 10, 2026

Atea Pharmaceuticals has secured a credit facility worth up to $200 million from Hercules Capital, with an initial $65 million received at closing. This non-dilutive financing aims to strengthen Atea's financial position and provide operational flexibility as it advances its late-stage clinical programs, including the anticipated launch of its hepatitis C virus (HCV) treatment. The funding will support the company's efforts towards key clinical and regulatory milestones, with a planned new drug application (NDA) submission in mid-2027 and potential US commercial launch in 2028.

Nov 10, 2026

Black Diamond Therapeutics announced positive updated Phase 2 results for silevertinib in frontline NSCLC patients with EGFR non-classical mutations, demonstrating robust CNS activity and an 86% CNS-ORR. The company also reported positive feedback from an End-of-Phase 2 meeting with the FDA, supporting a clear path to potential accelerated approval for silevertinib in this patient population. Black Diamond Therapeutics ended the third quarter of 2026 with $102.0 million in cash, which is expected to fund operations into the second half of 2028.

Nov 9, 2026

Marea Therapeutics announced positive results from Part A of its Phase 2b TYDAL-TIMI 78 trial for MAR001, showing significant reductions in triglycerides (39.1%-45.5%) without worsening glycemic control. The drug, a potential first-in-class ANGPTL4 inhibitor, demonstrated even greater efficacy in participants with higher baseline triglyceride levels. These findings, presented at AHA 2026 and published in NEJM, support MAR001/MAR005 as a promising treatment for severe hypertriglyceridemia, with Part B of the trial now enrolling.

Nov 9, 2026

Pfizer aims to become a leader in the rapidly expanding GLP-1 market, projected to reach $190 billion by 2035, despite its drug, berobenatide, potentially not launching until 2028. The company plans to introduce both weekly and monthly versions of the treatment, leveraging its strong commercial execution and expertise in large-scale product rollouts to overcome its late market entry. Pfizer believes its ability to manage distribution, counter counterfeit products, and potentially offer a more tolerable treatment option will secure it a significant share of the market.

Nov 9, 2026

Pfizer is confident it can become a dominant player in the GLP-1 market, projected to reach $190 billion by 2035, despite its drug, berobenatide, potentially not launching until 2028. The company plans to introduce both weekly and monthly versions of the treatment, leveraging its strong commercial execution, experience in scaling products, and ability to combat counterfeit goods. While berobenatide still needs regulatory approval, Pfizer's expertise and the market's vast potential suggest ample room for the company to carve out a significant share.

Nov 9, 2026

Delix Therapeutics, backed by Johnson & Johnson, has secured $100 million in a Series C funding round to advance its non-hallucinatory psychedelic therapy, zalsupindole, for depression. The therapy is a neuroplastogen designed to promote neuroplasticity without hallucinogenic effects. The funds will support a Phase 2b study in major depressive disorder (MDD) set to begin in early 2027, and further development of other neuroplastogens for various neurological and neurodegenerative diseases.

Nov 9, 2026

ImmunityBio announced that its Anktiva plus BCG combination therapy met its primary endpoint in a Phase 2b trial for BCG-naïve bladder cancer patients, showing improved efficacy over BCG alone. The company, however, withheld specific response rates and detailed statistical data, although it confirmed no new safety concerns. ImmunityBio plans to submit a supplemental biologics license application to the FDA by year-end 2026 to expand Anktiva's indication for earlier treatment.

Nov 9, 2026

Pfizer's stock is currently yielding 5.8%, paying investors as the company works to replace older drugs facing patent expirations. Management highlighted the loss of exclusive rights for Ibrance, Xtandi, and Eliquis as key factors for 2027, raising concerns that these patent losses could outpace the growth of new drugs. While current sales are holding steady, and the dividend appears covered by free cash flow, the true impact of these losses will become clearer with Pfizer's 2027 guidance in December and the fiscal Q4 2026 results in February 2027.

Nov 8, 2026

Precision BioSciences has revealed promising Phase 1 results for PBGENE-HBV, its gene-editing therapy for chronic hepatitis B. The study demonstrated biopsy-confirmed cccDNA elimination and near-complete pgRNA loss in all target-dose patients, addressing the long-standing challenge of the viral reservoir that current antivirals cannot tackle. This development offers a potential turning point for the 254 million people worldwide living with chronic hepatitis B, a disease currently without a true cure.

Nov 7, 2026

Boston Trust Walden Corp significantly increased its stake in Regeneron Pharmaceuticals, Inc. by 794.1% in the third quarter, acquiring 9,474 additional shares to reach a total of 10,667 shares valued at $8.1 million. This increase comes as Regeneron reported strong quarterly earnings, beating analyst expectations with an EPS of $20.07 and revenue up 36.3% year-over-year. Despite recent insider selling, analysts maintain a "Moderate Buy" consensus rating for the company.

Nov 7, 2026

Evommune has licensed global development rights outside Greater China for EVO570, an experimental oral drug for inflammatory diseases, from Hinova Pharmaceuticals. The deal includes $20 million in cash and $10 million in warrants, alongside potential royalties and milestone payments. Evommune also raised an additional $30 million, extending its cash runway into the second half of 2029, to advance EVO570 for rheumatoid arthritis, with Phase I trials expected to begin in January 2027.

Nov 6, 2026

Johnson & Johnson's bispecific antibody drug, Rybrevant Faspro, has received accelerated FDA approval for treating advanced head and neck squamous cell carcinoma. This expands the drug's use beyond its initial approval for certain lung cancers. The approval is based on clinical trial results showing a 42% overall response rate in patients, with a Phase 3 trial ongoing to confirm efficacy and potentially support first-line treatment.

Nov 6, 2026

Bristol Myers Squibb's dividend, currently yielding over 4%, appears durable despite an anticipated $1.5 billion to $2 billion drop in Eliquis sales in 2027 and significant debt. The company's payout ratios are low (around 40% of earnings and 39% of free cash flow), and debt has been decreasing. While dividend growth may be slow as the company prioritizes debt reduction and business development, its long history of payments suggests resilience.

Nov 6, 2026

Rigel Pharmaceuticals Inc (RIGL) reported record net product sales of $72.3 million in Q3 2026, a 13% year-over-year increase, driven by the strong launch of VEPPANU. The company achieved a net income of $13.2 million for the quarter and anticipates full-year profitability, while also advancing its R289 pipeline asset. Despite some declines in GAVRETO sales and increased expenses, the company expressed confidence in its diversified commercial portfolio and future growth prospects.

Nov 6, 2026

Accendra Health reported a significant drop in net revenue and adjusted EBITDA for Q3 2026, falling short of expectations and leading to a review of their strategy. CVS Health announced its intention to separate into two independent, publicly traded companies: a health care solutions company and a national retail pharmacy and community health care company. Meanwhile, CMS finalized several policies in the Home Health Prospective Payment System, including retroactive revocations and DME expansion for infusion pumps.

Nov 5, 2026

Halozyme Therapeutics reported strong Q3 2026 financial results with a 39% increase in total revenue to $493 million and a 44% rise in royalty revenue to $341 million, driven by the continued growth of ENHANZE-enabled products like Darzalex Subcutaneous and Vyvgart Hytrulo. The company expanded its ENHANZE opportunity with new target nominations and advanced multiple programs into clinical development, raising its full-year 2026 revenue guidance. Halozyme also secured significant legal victories in Europe against Merck regarding its Keytruda subcutaneous patent, preventing its launch in key markets, and is progressing its HyperCon and AeroCon hyperconcentration technologies towards clinical trials in 2027 and 2028, respectively.

Nov 5, 2026

A new report by DelveInsight details the Achondroplasia pipeline for 2026, highlighting over 10 key companies developing novel treatments. The report outlines ongoing clinical trials, therapeutic mechanisms, and market growth prospects. Key companies include BioMarin Pharmaceuticals and BridgeBio/QED Therapeutics, with several therapies nearing significant regulatory milestones like FDA approvals.

Nov 5, 2026

Halozyme Therapeutics (NASDAQ:HALO) reported better-than-expected Q3 2026 revenue of $493 million, up 39.2% year-on-year, and raised its full-year revenue and EBITDA guidance. Despite these positive financial results and strong long-term revenue growth, the company's stock dropped by 5.6% immediately after the announcement. The decline was attributed to the market potentially hoping for even stronger results, despite the solid performance.

Nov 5, 2026

Silicon Valley tech executives are making grand claims about AI's ability to cure most human diseases within a decade, with one even joking that AI will cure lung cancer. However, pharmaceutical CEOs are skeptical, noting that no drug designed by AI has yet received FDA clearance. They argue that the primary obstacle to developing new drugs remains biology, not a lack of technological advancement.

Nov 5, 2026

Revolution Medicines' new RAS inhibitor, Rasonque (daraxonrasib), achieved "eye-popping" initial sales of $197.6 million in just five weeks after its August 26 approval, significantly exceeding analyst expectations. Despite this strong performance, RevMed leadership is cautiously optimistic, noting that initial sales were boosted by temporary factors like expanded access switches and patients awaiting therapy. The drug is now being prepared for launch in the European Union and Japan following regulatory approvals.

Nov 5, 2026

Halozyme Therapeutics reported better-than-expected Q3 2026 revenue of $493 million, a 39.2% year-on-year increase, and raised its full-year revenue and adjusted EPS guidance. Despite strong financial performance and expanded agreements, the company's stock dropped 5.6% immediately after the results were announced. The article details the company's financial highlights, revenue and EPS growth, and adjusted operating margins.

Nov 5, 2026

Processa Pharmaceuticals has released a stockholder letter detailing its July 2026 acquisition of Vidya Therapeutics and its plans for the lead candidate VT-7208. The acquisition, coupled with a private placement, raised $183.3 million, expected to fund operations through mid-2029. The FDA has approved an IND application for VT-7208's Phase 2 trial in Chronic Spontaneous Urticaria, with development also targeting food allergy and relapsing multiple sclerosis.

Nov 5, 2026

Xeris Biopharma reported a strong third quarter with sales up 44 percent to US$107.2 million and net income climbing to US$11.3 million. The company raised its full-year 2026 revenue forecast to US$395 million to US$405 million, driven by strong demand for its drug Recorlev. Xeris also remains on track to initiate a pivotal Phase 3 thyroid-treatment study by the end of 2026 and expects over US$1 billion in total revenue by 2030.

Nov 5, 2026

Indian drugmaker Dr Reddy's Laboratories has received regulatory approval in Brazil to market and sell a generic version of Novo Nordisk's diabetes drug Ozempic. Brazil has a significant population of adults living with diabetes, making this a key market. Dr Reddy's plans to relaunch generic semaglutide in Canada this quarter and target launches in Latin America and Africa in the coming months.

Nov 5, 2026

Rakuten Investment Management Inc. increased its stake in Regeneron Pharmaceuticals, Inc. by 8.6% during the third quarter, bringing their total holdings to $20,033,000. Other institutional investors also adjusted their positions in the biopharmaceutical company, while several analysts issued "Buy" or "Overweight" ratings with an average price target of $898.97. Additionally, two directors sold shares totaling over $7.9 million, and Regeneron announced a quarterly dividend of $0.94 per share.

Nov 5, 2026

electroCore (ECOR) reported record net sales of $9.7 million in Q3 2026, a 12% increase year-over-year, and achieved its lowest operating loss in company history with adjusted EBITDA loss improving by 67% to $700,000. The company is undergoing a commercial transformation, focusing on profitable, long-term revenue growth and expanding its VA market penetration for gammaCore and Quell devices. Despite revising full-year 2026 revenue guidance, electroCore anticipates accelerated growth of 30% to 40% in 2027, driven by sales organization changes, increased VA account staffing, and potential clearance for Quell in chemotherapy-induced peripheral neuropathy (CIPN).

Nov 4, 2026

Adaptive Biotechnologies (NASDAQ: ADPT) reported strong Q3 2026 financial results, achieving profitability ahead of expectations with a 44% year-over-year increase in MRD revenue. The company raised its full-year 2026 MRD revenue guidance, driven by robust clinical testing volumes and pharma sequencing. Strategic advancements include expanded commercial and Medicaid coverage for clonoSEQ, active engagement with MolDX for a multiple myeloma maintenance testing bundle, and significant growth in its MRD pharma business backlog.

Nov 4, 2026

AutoZone Inc. officer Jamere Jackson filed a Form 144 with the SEC, announcing his intention to sell 6,900 shares of AutoZone common stock. These shares, valued at approximately $22.9 million, were acquired through a stock option exercise on November 4, 2026, the same day the sale is scheduled to occur via Fidelity Brokerage Services LLC on the NYSE. The filing confirms no prior sales by Jackson in the preceding three months.

Nov 4, 2026

Olema Oncology announced it will present clinical data from three Phase 1b/2 and Phase 1 studies at the 2026 San Antonio Breast Cancer Symposium (SABCS) in December. The presentations will cover combination data for OP-3136 with fulvestrant, palazestrant with everolimus, and palazestrant with atirmociclib, all in patients with ER+, HER2- advanced or metastatic breast cancer. This highlights Olema's ongoing efforts to develop novel targeted therapies for breast cancer.

Nov 4, 2026

Shares of Nurix Therapeutics (NRIX) fell 38% after Sanofi discontinued the development of an experimental oral drug, SAR448272, that it had licensed from Nurix. Wells Fargo subsequently lowered its price target on Nurix to $20 from $25, maintaining an Equal Weight rating, citing the loss of an asset to which it had attributed $400 million in value and the elimination of potential milestone payments. Despite the setback, Nurix maintains a strong cash position expected to fund operations into the second half of 2029.

Nov 4, 2026

Huntington Sec initiated coverage on Sabra Healthcare REIT (NASDAQ:SBRA) with a "strong-buy" rating. This new rating follows other analyst reports, with the stock currently holding an average rating of "Moderate Buy" and a consensus price target of $21.50. The company recently reported mixed Q3 2026 earnings, missing EPS estimates but exceeding revenue expectations, and also increased its 2026 guidance.

Nov 4, 2026

CNBC's "Halftime Report Final Trades" featured picks from several market strategists. Joshua Brown recommended Amazon.com (AMZN) despite its recent worse-than-expected Q3 earnings. Jim Lebenthal suggested BlackRock (BLK), noting it's ready to break out after reporting better-than-expected Q3 financial results. Jason Snipe chose Eaton Corporation (ETN) due to its upbeat Q3 results and raised guidance, while Joseph M. Terranova recommended Pfizer (PFE) following its strong Q3 sales and earnings beat.

Nov 3, 2026

Nurix Therapeutics announced that Sanofi has decided to discontinue the development of SAR448272, an oral STAT6 degrader, and terminate its associated program. This decision means Nurix will not receive future milestone payments or royalties for this specific program. However, Nurix's other partnered programs with Sanofi and its wholly owned pipeline remain active, and the company maintains a strong cash runway extending into the second half of 2029.

Nov 3, 2026

Pfizer reported flat third-quarter revenue and earnings, though sales excluding COVID products were up 7%, leading management to raise its 2026 guidance. While COVID product and Prevnar sales faced headwinds, other therapies like Padcev, Lorbrena, Eliquis, Vyndamax, and Nurtec showed strong growth. Morningstar maintains its $32 fair value estimate for Pfizer, anticipating pipeline progress in obesity, oncology, and immunology will help offset upcoming patent expirations, though revenue declines are still projected for 2028 and 2029.

Nov 3, 2026

Moderna's stock surged 5% ahead of its earnings report, extending a 685% year-to-date rally, despite being unprofitable with a small revenue base. Pfizer's shares eased 0.8% despite exceeding revenue estimates and raising its full-year guidance, as declining COVID-19 product sales were offset by other drug increases. Merck's stock dropped 2% following the launch of a new Phase 3 trial for Ohtuvayre to prevent COPD exacerbations, even though the company is up 40% year-to-date.

Nov 3, 2026

Moderna's stock surged 5% ahead of its earnings report, extending a significant year-to-date rally. Meanwhile, Pfizer eased despite raising its full-year outlook and beating revenue estimates, influenced by declining COVID product sales. Merck's shares fell 2% even after the company initiated a new Phase 3 trial for COPD prevention.

Nov 3, 2026

Pfizer reported strong Q3 2026 results, beating EPS and revenue estimates and raising full-year guidance, driven by non-COVID product growth and cost savings. Despite the positive earnings, the stock saw a slight dip, indicating that much of the good news may have already been priced in. Future challenges include shrinking earnings estimates due to loss of exclusivity on major products and the absence of buybacks, with upcoming catalysts including 2027 guidance and pipeline milestones.

Nov 3, 2026

The Investment Committee has identified its top stock picks for the second half of the year, focusing on Amazon (AMZN), BlackRock Inc. (BLK), Eaton Corp. (ETN), and Pfizer (PFE). This report provides a quick overview of these selected companies.

Nov 3, 2026

Merck recently posted its sixth consecutive earnings beat, raising its 2026 profit outlook and setting a mid-2030s revenue target of $70 billion. Despite this success, the stock faces a looming patent cliff for its blockbuster drug Keytruda, leading 24/7 Wall St. to assign a "HOLD" rating with a price target implying a 15.67% downside. The company's pipeline, including drugs like Sac-TMT and Lipfendra, is crucial for offsetting potential losses from generic competition and driving future growth.

Nov 3, 2026

Rockwell Medical has agreed to acquire the majority of Vantive's hemodialysis business for $125 million in base consideration, with an additional $45 million in contingent payments. The deal includes hemodialysis concentrates, machines, water treatment systems, and Vantive's Medolla, Italy manufacturing facility, with the combined entity projected to generate $400-450 million annually. Vantive will retain its dialyzer portfolio and focus on home dialysis and critical care post-divestiture, while Rockwell aims to accelerate its growth in hemodialysis.

Nov 3, 2026

Pfizer (NYSE: PFE) reported strong third-quarter results, with sales of $16.58 billion and adjusted earnings of 87 cents per share, both exceeding analyst consensus. The company's non-COVID product portfolio demonstrated significant operational revenue growth of 7%, offsetting declines in COVID-19 related products. Bolstered by these results, Pfizer raised its full-year 2026 sales and adjusted earnings guidance, signaling confidence in its long-term growth strategy and pipeline developments.

Nov 3, 2026

Pfizer has raised its full-year guidance, with strong sales from new and acquired products helping to counterbalance a decline in revenue from its COVID-19 vaccine and treatments. The company's recently launched cancer treatments and other key products like Eliquis and Vyndaqel saw significant growth, contributing to an overall 7% increase in sales from non-Covid products. This positive momentum led Pfizer to project annual sales of $62 billion to $64 billion.

Nov 3, 2026

Seres Therapeutics announced the publication of Phase 1b results for SER-155 in Nature Medicine, showing a 77% relative risk reduction in bloodstream infections among allogeneic hematopoietic cell transplantation recipients compared to placebo. The study also demonstrated significantly lower systemic antibiotic exposure and supported SER-155's mechanisms of strengthening the gut barrier and reducing inflammation. SER-155 has FDA Breakthrough Therapy and Fast Track designations and is Phase 2-ready, pending funding.

Nov 3, 2026

CorVel Corporation reported an 11% year-over-year increase in revenue, reaching $267 million for its fiscal second quarter ending September 30, 2026. The company also saw diluted earnings per share grow by 24% to $0.67 and gross profit increase by 24% to $72.3 million. CorVel maintained a strong financial position with $270 million in cash and no borrowings, after repurchasing $18.1 million of its common stock.

Nov 3, 2026

Ahead of its Q3 earnings report, analysts anticipate Pfizer (NYSE: PFE) to report a decrease in quarterly earnings to 73 cents per share and revenue of $15.88 billion. Several Wall Street analysts have recently updated their ratings and price targets for Pfizer, with ratings ranging from Neutral to Buy and price targets between $28 and $33. The company recently released positive topline results from its Phase 3 MagnetisMM-32 study for Elrexfio.

Nov 3, 2026

Palvella Therapeutics Inc. has received priority review from the FDA for its experimental drug QTORIN 3.9% rapamycin anhydrous gel, intended for microcystic lymphatic malformations. This rare disease treatment, if approved by the target date of February 28, 2027, would be the first FDA-approved therapy for the condition. The company is preparing for a commercial launch in the first half of 2027, supported by positive Phase 3 trial results and various FDA designations.

Nov 3, 2026

Tempus AI (NASDAQ:TEM) reported its first adjusted profit and record third-quarter revenue, driven by accelerated oncology testing growth and strong demand for its data and applications segment. The company also raised its full-year revenue outlook, signaling a positive turn for the AI-driven healthcare platform. These results demonstrate Tempus AI's ability to translate its extensive data scale into significant financial gains, despite a challenging broader technology market.

Nov 3, 2026

Pfizer (PFE) reported better-than-expected Q3 2026 financials, leading the company to hike its full-year 2026 outlook. This positive revision comes despite relatively flat quarterly revenue due to decreased demand for its COVID-19 products. Additionally, Pfizer announced the appointment of Cecile Guegan as its new CFO.

Nov 3, 2026

As U.S. stock futures show mixed trading, investors are focusing on several key companies. Pfizer Inc. is expected to report earnings of 72 cents per share on revenue of $15.87 billion. Apple Inc. reported strong Q4 2026 earnings but anticipates a decline in gross margin for the holiday quarter, causing its shares to drop. Keurig Dr Pepper Inc., Palantir Technologies Inc., and Advanced Micro Devices Inc. also have upcoming earnings reports or recent financial results that are influencing their stock performance.

Nov 3, 2026

Regeneron Pharmaceuticals (NASDAQ: REGN) declared a quarterly dividend of $0.94 per share, payable on December 3rd to shareholders of record on November 20th. This translates to an annualized dividend of $3.76, representing a 0.4% yield, which is well covered by the company's earnings. The announcement follows a strong quarter where Regeneron exceeded expectations with EPS of $20.07 and revenue of $5.12 billion, leading to a 3.6% increase in share price to $961.26 and several analyst target raises.

Nov 2, 2026

Lakefront Biotherapeutics NV announced the appointment of Dr. Mehdi Shahidi as a Non-Executive Independent Director to its Board, effective November 2, 2026. Dr. Shahidi brings over 20 years of biopharma experience in drug development, regulatory success, and R&D leadership. He replaces Dr. Paulo Fontoura, who resigned in July 2026.

Nov 2, 2026

Advanced Micro Devices (NASDAQ: AMD) is among seven companies expected to experience significant stock price swings after their upcoming earnings reports. Options traders are pricing in a 10.85% move for AMD, translating to approximately $90.7 billion in market value due to its large market cap. The article highlights other companies like Pfizer, Amgen, Booking Holdings, Eaton, Arista Networks, and Shopify, detailing their implied stock movements and financial expectations.

Nov 2, 2026

Vise Technologies Inc. recently acquired 38,406 shares of Amgen Inc. during the third quarter, a stake valued at approximately $16.19 million. Institutional investors collectively own 76.5% of Amgen's outstanding stock, while analyst ratings are mixed, with an average "Hold" rating and a consensus price target of $389.71. Amgen reported strong quarterly earnings, exceeding revenue and EPS estimates, and declared a quarterly dividend of $2.52 per share.

Nov 2, 2026

ProShare Advisors LLC decreased its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 1.9% during the third quarter, selling 2,206 shares while retaining 117,034 shares valued at $88.7 million. The biopharmaceutical company reported strong third-quarter results, exceeding analyst expectations with revenue up 36.3% year-over-year to $5.12 billion and non-GAAP EPS of $20.07. Analysts maintain a "Moderate Buy" rating for REGN, despite potential volatility from biosimilar competition for Eylea and valuation concerns.

Nov 2, 2026

This article explains how investors can earn $500 a month from Pfizer's dividend yield ahead of its Q3 earnings report. It details the investment required—approximately $106,454 or 3,488 shares—to achieve this income based on Pfizer's current 5.64% annual dividend yield. The piece also clarifies how dividend yield is calculated and affected by changes in stock price and dividend payments, noting that Pfizer shares recently gained 1.9% and analysts expect quarterly earnings of 73 cents per share.

Nov 2, 2026

Pfizer (NYSE:PFE) is scheduled to report its Q3 earnings before market open on Tuesday, with analysts expecting a 4.8% year-on-year revenue decline. The company beat revenue expectations last quarter but missed full-year EPS guidance. Investors in the branded pharmaceuticals segment, including Pfizer, have shown positive sentiment recently.

Nov 1, 2026

Exelixis (EXEL) saw its stock return 76.0% between October 2025 and October 2026, significantly outperforming the S&P 500. This surge followed the FDA's acceptance of its experimental cancer drug, zanzalintinib, which the company had been highlighting to investors since February 2025. Despite public trial results showing positive outcomes, the stock's major run-up occurred later when the regulatory process advanced.

Oct 31, 2026

Pfizer shares have risen 20% year-to-date, hitting a new 52-week high, signaling a potential turnaround from its post-pandemic slump. This progress is attributed to cost-cutting, better-than-expected sales of non-COVID drugs, and a promising pipeline, despite the upcoming patent expirations for key blockbusters. While uncertainty remains, the company's sustainable dividend yield and efforts to stabilize earnings suggest a path for continued growth as it navigates these challenges.

Oct 30, 2026

AstraZeneca has terminated a Phase III trial for its blockbuster drug Ultomiris, which aimed to expand its use to treat delayed graft function in kidney transplant patients, due to a low probability of meeting the primary efficacy endpoint. Despite this setback, Ultomiris remains approved for five rare disease indications and generated significant revenue in Q3, with analysts projecting continued strong sales. The drug was found safe and tolerable in the trial, and AstraZeneca is pursuing further indications for it.

Oct 30, 2026

Pfizer Inc. (PFE) shares increased by 1.90% to $30.52 on Friday, in contrast to a general market downturn where the S&P 500 Index and Dow Jones Industrial Average both fell. This marks the second consecutive day of gains for the stock.

Oct 30, 2026

An investment of $250,000 split evenly across UnitedHealth Group, Merck, AbbVie, and Pfizer could generate approximately $8,018 in annual passive income, offering a blended yield of 3.21%. While Pfizer provides the highest income, it also presents the most risk due to a frozen dividend. AbbVie and UnitedHealth show greater dividend safety with recent raises and wider coverage cushions, making healthcare a stable sector for retirement income.

Oct 30, 2026

AstraZeneca has announced a $1.5 billion cost-savings program to free up resources for investment in its drug pipeline. This plan was revealed alongside its third-quarter results, which showed increased revenue and profit driven by strong cancer drug sales, despite patent expirations. The U.K. drugmaker aims to redeploy these resources across its existing business and therapy areas over the next three years.

Oct 30, 2026

Pfizer has been downgraded from 'Buy' to 'Hold' due to increasing bearish analyst sentiment and dimming growth prospects, with consensus revenue and EPS expected to decline through 2029. While cost-cutting efforts and pipeline updates, including anti-obesity drugs, are critical, they are unlikely to offset impending patent cliffs. The sustainability of the dividend is also in question, as payouts almost match free cash flow, and intrinsic value is estimated at $28.39.

Oct 30, 2026

BridgeBio Pharma reported strong financial results for Q3 2026, with total revenues of $353.2 million, driven by acoramidis sales and a $75 million milestone from Bayer. The company is preparing for three significant product launches—BBP-418, infigratinib, and encaleret—all under priority review with the FDA. BridgeBio remains confident in its acoramidis franchise, projecting $4 billion in peak-year sales, and highlights compelling real-world evidence differentiating it from competitors.

Oct 30, 2026

A Pfizer manufacturing plant in Gujarat, India, that produces generic chemotherapy drugs for the U.S. is expected to remain closed until 2028 due to flood damage, as reported by the American Society of Health-System Pharmacists (ASHP). This extended closure will exacerbate existing shortages of critical chemotherapy agents, impacting treatment planning for various cancers. Patients are advised to consult their oncology teams regarding their specific regimens and potential alternatives, while policy efforts are underway to address drug supply vulnerabilities.